Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

BACKGROUND: Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the safety and efficacy of camrelizumab plus neoadjuvant chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun, Yang, Yang, Liu, Zhichao, Fu, Xiaolong, Cai, Xiaoyue, Li, Hongxuan, Zhu, Li, Shen, Yan, Zhang, Hong, Sun, Yifeng, Chen, Hezhong, Yu, Bentong, Zhang, Renquan, Shao, Jinchen, Zhang, Ming, Li, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961177/
https://www.ncbi.nlm.nih.gov/pubmed/35338088
http://dx.doi.org/10.1136/jitc-2021-004291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961177/
https://www.ncbi.nlm.nih.gov/pubmed/35338088
http://dx.doi.org/10.1136/jitc-2021-004291

Ejemplares similares